Visual fields and ocular surface - what is important for my glaucoma patients?
This webinar provides an overview on the latest data on the relationship between ocular surface disease and topical antiglaucoma therapy and the impact of visual field loss in patients’ daily lives.
The webinar, organised and funded by Santen, provides an overview on the latest data on the relationship between ocular surface disease and topical antiglaucoma therapy and the impact of visual field loss in patients’ daily lives.
Learning Objectives of Webinar
- Ocular surface disease is more prevalent with patients treated with preserved mediations.
- Preservatives BAK and Polyquad have a high impact on ocular surface health.
- Visual field loss can have a significant impact on patient’s quality of life.
